Takeda Pharmaceutical Li...

NYSE: TAK · Real-Time Price · USD
14.80
0.03 (0.20%)
At close: Aug 14, 2025, 3:59 PM
14.83
0.17%
Pre-market: Aug 15, 2025, 07:00 AM EDT

Takeda Pharmaceutical Income Statement

Financials in JPY. Fiscal year is April - March.
Fiscal Year FY 2024 FY 2023 FY 2022 FY 2021
Period Ending Mar 31, 2025 Mar 31, 2024 Mar 31, 2023 Mar 31, 2022
Revenue
4,581.6B 4,263.8B 4,027.5B 3,569B
Cost of Revenue
1,580.2B 1,431.5B 1,244.1B 1,106.8B
Gross Profit
3,001.3B 2,832.3B 2,783.4B 2,462.2B
Operating Income
342.59B 214.07B 490.5B 460.84B
Interest Income
n/a 11.29B 62.91B 23.7B
Pretax Income
175.08B 52.79B 375.09B 302.57B
Net Income
107.93B 144.07B 317.02B 230.06B
Selling & General & Admin
1,104.8B 1,053.8B 997.31B 886.36B
Research & Development
730.23B 729.92B 633.33B 526.09B
Other Expenses
823.75B 834.44B -9.47B 588.87B
Operating Expenses
2,658.7B 2,618.2B 2,292.9B 2,001.3B
Interest Expense
n/a 153.63B 169.7B 166.61B
Selling & Marketing Expenses
n/a n/a n/a n/a
Cost & Expenses
4,239B 4,049.7B 3,537B 3,108.2B
Income Tax Expense
66.94B -91.41B 58.05B 72.41B
Shares Outstanding (Basic)
3.21B 3.13B 3.1B 3.13B
Shares Outstanding (Diluted)
3.21B 3.16B 3.14B 3.15B
EPS (Basic)
34.17 46.05 102.15 73.57
EPS (Diluted)
33.62 45.58 100.97 72.94
EBITDA
1,210.5B 874.6B 1,184.5B 1,183.2B
EBIT
449.12B 172.33B 492.06B 425B
Depreciation & Amortization
761.4B 728B 664.4B 583.15B